Resultados de Búsqueda
I is not recommended to adopted the routine use of Mepilex Border Heel and Sacrum to prevent pressure ulcers in people considered to be at risk in acute care settings.
NICE
Link to the recommendation on the website of the initiative / Enlace a la recomendación en la página
Mepilex Border Heel and Sacrum dressings show promise for preventing pressure ulcers in people who are considered to be at risk in acute care settings. However, there is currently insufficient evidence to support the case for routine adoption in the NHS. Research is recommended to address uncertainties about the claimed benefits of using Mepilex Border Heel and Sacrum dressings. This research should also explore issues such as: the incidence of heel and sacrum pressure ulcers in NHS acute ...
ver más ... 2019It is recommended adopting the Debrisoft monofilament debridement pad as part of the management of acute or chronic wounds in the community.
NICE
National Institute for Health and Clinical Excellence (NICE)
La evidencia disponible es limitada, pero los beneficios probables de usar la almohadilla Debrisoft en las heridas apropiadas son que se desbridarán por completo más rápidamente, con menos visitas de enfermería necesarias, en comparación con otros métodos de desbridamiento. Además, la almohadilla Debrisoft es conveniente y fácil de usar, y los pacientes la toleran bien. El desbridamiento es un componente importante del manejo estándar del cuidado de heridas como se describe en las ...
ver más ... 2019It is recommended to adopting UrgoStart dressings to treat diabetic foot ulcers and venous leg ulcers in the NHS, because they are associated with increased wound healing compared with ...
NICE
National Institute for Health and Clinical Excellence (NICE)
UrgoStart dressings should therefore be considered as an option for people with diabetic foot ulcers or venous leg ulcers after any modifiable factors such as infection have been treated. Cost modelling shows that, compared with standard care, using UrgoStart dressings to treat diabetic foot ulcers is associated with a cost saving of £342 per patient after 1 year. It also shows that UrgoStart is likely to be cost saving for treating venous leg ulcers, but the robustness of this conclusion is ...
ver más ... 2019Pembrolizumab, with carboplatin and paclitaxel, is recommended for use within the Cancer Drugs Fund as an option for untreated metastatic squamous non-small-cell lung cancer (NSCLC) in adults
NICE
National Institute for Health and Clinical Excellence (NICE)
Current treatment for untreated metastatic squamous NSCLC is usually platinum-based combination chemotherapy (standard chemotherapy) for people whose tumours express PD‑L1 with a tumour proportion score of lower than 50%, or pembrolizumab monotherapy for people whose tumours express PD‑L1 with a tumour proportion score of 50% or higher. The main clinical evidence for pembrolizumab with carboplatin and paclitaxel (pembrolizumab combination therapy) comes from an ongoing randomised controlled ...
ver más ... 2019Cemiplimab is recommended for use within the Cancer Drugs Fund as an option for treating locally advanced or metastatic cutaneous squamous cell carcinoma in adults when curative surgery or curative ...
NICE
National Institute for Health and Clinical Excellence (NICE)
Living with advanced unresectable cutaneous squamous cell carcinoma is physically and emotionally challenging, and there is a high unmet need for new treatments. Cemiplimab trial data are promising but uncertain. The cost-effectiveness estimates for cemiplimab are above what is normally considered a cost-effective use of NHS resources. The evidence on life expectancy with current treatments and how long life might be prolonged with cemiplimab is very uncertain. Because of this it is not known ...
ver más ... 2019